For a 55‑year‑old nonsmoking woman with hypertension who has hot flashes, sleep disruption, vaginal dryness, and dyspareunia, which of the following is the best first‑line treatment: (1) oral estrogen alone, (2) oral estrogen plus progesterone, (3) oral gabapentin, or (4) vaginal estrogen therapy?

Best First-Line Treatment: Oral Estrogen Plus Progesterone

For this 55-year-old nonsmoking woman with hypertension experiencing both vasomotor symptoms (hot flashes, sleep disruption) AND genitourinary symptoms (vaginal dryness, dyspareunia), oral estrogen plus progesterone is the best first-line treatment 1, 2.

Rationale for This Recommendation

This patient has an intact uterus (no mention of hysterectomy) and presents with both systemic vasomotor symptoms and genitourinary symptoms. This clinical picture requires systemic hormone therapy, not just local treatment.

Why Oral Estrogen Plus Progesterone (Option 2):

• Systemic estrogen is the most effective treatment for vasomotor symptoms, reducing hot flash frequency by approximately 75% 2
• Progestogen is mandatory in women with an intact uterus to prevent endometrial hyperplasia and adenocarcinoma 1
• Addresses all her symptoms simultaneously: hot flashes, sleep disruption, vaginal dryness, and dyspareunia 1, 2
• She is 55 years old (within the therapeutic window of <60 years or <10 years from menopause onset) 2, 3
• Her only cardiovascular risk factor is hypertension, which is manageable

Why NOT the Other Options:

Option 1 (Oral Estrogen Alone): Absolutely contraindicated. She has an intact uterus and requires progestogen protection. Unopposed estrogen dramatically increases endometrial cancer risk 1.

Option 3 (Oral Gabapentin): While gabapentin reduces vasomotor symptoms by approximately 40-65% 2 and one study showed 71% reduction in hot flush composite score 4, it is second-line therapy reserved for women who cannot take hormones. Gabapentin does NOT treat genitourinary symptoms (vaginal dryness, dyspareunia) 5. Additionally, gabapentin causes significant adverse effects including dizziness, somnolence, and disorientation—with number needed to harm of 4 patients 4. It would leave half her symptoms untreated.

Option 4 (Vaginal Estrogen Alone): Low-dose vaginal estrogen effectively treats genitourinary symptoms with 60-80% improvement 2, 6, but provides minimal systemic absorption and does NOT adequately treat vasomotor symptoms like hot flashes 1. This would leave her most bothersome systemic symptoms (hot flashes, sleep disruption) untreated.

Important Considerations for Hypertension

Her hypertension requires attention when selecting hormone formulation:

• Oral conjugated equine estrogens (CEE) plus progestogen increase systolic blood pressure (SMD = 0.60 mm Hg) and hypertension risk 7
• Transdermal estradiol plus progestogen does NOT significantly affect blood pressure (SMD = -2.00 mm Hg, 95% CI = -7.26 to 3.27) 7
• Consider transdermal estradiol over oral CEE given her hypertension, as transdermal formulations also carry lower venous thromboembolism risk 3, 8

Treatment Algorithm

1. Start systemic estrogen plus progestogen (she has intact uterus)
2. Prefer transdermal estradiol over oral CEE due to hypertension
3. Use micronized progesterone if available (lower VTE risk than medroxyprogesterone acetate) 3
4. Monitor blood pressure closely during initiation
5. Use lowest effective dose and reassess periodically 1
6. If systemic therapy alone doesn't fully resolve vaginal symptoms after 8-12 weeks, add low-dose vaginal estrogen 1

Common Pitfalls to Avoid

• Never give unopposed estrogen to women with intact uterus—endometrial cancer risk is unacceptable
• Don't use gabapentin as first-line when hormones are not contraindicated—it's less effective and doesn't treat genitourinary symptoms
• Don't use vaginal estrogen alone for patients with significant vasomotor symptoms—systemic absorption is insufficient
• Don't avoid hormone therapy solely due to controlled hypertension—choose transdermal formulation instead 7